Report cover image

South & Central America Therapeutic Vaccines Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

Publisher The Insight Partners
Published Sep 01, 2025
Length 118 Pages
SKU # TIP20577537

Description

The therapeutic vaccines market in South and Central America is projected to grow significantly, reaching approximately US$ 6,998.78 thousand by 2031, up from US$ 3,370.35 thousand in 2024, reflecting a compound annual growth rate (CAGR) of 11.0% from 2024 to 2031.

Executive Summary and Market Analysis

The market is divided into key regions: Brazil, Argentina, and the Rest of South and Central America. Growth in this sector is driven by a large population, improving healthcare infrastructure, and an increasing governmental emphasis on healthcare innovation. Additionally, rising healthcare expenditures and a growing demand for treatments due to the prevalence of chronic diseases further stimulate market expansion.

Market Segmentation

The therapeutic vaccines market is categorized by product type, technology, and end user:

By Product: The market includes cancer vaccines, infectious disease vaccines, and others, with cancer vaccines dominating the market share in 2024.
By Technology: The market is divided into allogenic and autologous vaccines, with allogenic vaccines holding the largest share in 2024.
By End User: The primary end users are hospitals, clinics, and others, with hospitals accounting for the largest market share in 2024.

Market Outlook

The therapeutic vaccines sector is experiencing robust investment and advancements in vaccine development, driven by the increasing global demand for innovative treatment options. There is a notable rise in clinical candidates advancing through various development stages. Innovative research and development in biotechnology are leading to the creation of advanced therapeutic vaccines targeting a range of diseases, particularly chronic conditions like cancer and newer infections.

For instance, Moderna's mRNA-4157 is currently in phase 2 trials, showing promising results in combination with checkpoint inhibitors for melanoma treatment. The therapeutic vaccine pipeline is also expanding in areas such as autoimmune diseases and infectious diseases, including HIV, HPV, and HBV infections.

Numerous companies are focusing on scientific and technical excellence to develop and launch new therapeutic vaccines. The expanding pipeline of vaccine candidates targeting diverse diseases presents significant opportunities to meet unmet medical needs. Below is a summary of the therapeutic vaccine pipeline:

Vaccine Type, Vaccine Formulation, Phase/Status, Condition

Bacterial vector vaccine, ADXS11–001 (attenuated live Listeria Encoding HPV 16 E7 vector), Phase I/II, Cervical carcinoma, Anal cancer, Rectal cancer
Peptide/protein vaccine, ISA101 (nine HPV-16 E6 and four HPV-16 E7 synthetic peptides with Montanide ISA51), Phase II, Solid tumors
Personalized peptide vaccine, NeoVax (neoantigen + Poly-ICLC), Phase I, Kidney cancer
mRNA-based neoantigen vaccine, mRNA-4157 (lipid-encapsulated RNA), Phase I/II, Solid tumors, Melanoma
DNA vaccine, VGX-3100 (plasmid encoding E6 and E7 of HPV16/18), Phase I/II, Head and neck squamous cell cancer, Cervical cancer
Virus-like particle, NASVAC (HBsAg, HBcAg), Phase III, HBV infection
Protein vaccine, Theravax (DV-601, consisting of HBsAg, HbcAg, and saponin-based ISCOMATRIX adjuvant), Phase II, Chronic HBV infection
mRNA vaccine, iHIVARNA (consisting of HIV immunogen sequence and a mixture of activation molecules), Phase I, HIV infection
Viral vector vaccines, AdCh3NSmut/Ad6NSmut (encoding HCV proteins), Phase I, HCV infection
DNA vaccine, pNGVL4a-Sig/E7(detox)/HSP70 (HPV16 E7), Phase I, HPV infection

With numerous clinical trials underway, the market's future looks promising, offering new treatment options for patients and addressing unmet medical needs in areas where existing treatments fall short. The strong pipeline of therapeutic vaccine candidates indicates substantial growth potential for the market.

Country Insights

The therapeutic vaccines market in South and Central America includes Argentina, Brazil, and the Rest of South and Central America, with Brazil holding the largest market share in 2024. Brazil's market potential is bolstered by its large population, improving healthcare infrastructure, and a governmental focus on healthcare innovation. As of 2022, over 30 million Brazilians were aged 60 and above, a figure expected to rise to nearly 50 million by 2030, representing 24% of the population. The country faces a high incidence of chronic diseases and cancers, creating a significant health burden. According to GLOBOCAN 2020, Brazil reported 592,212 cancer cases, highlighting the need for effective therapeutic vaccines to alleviate this burden. As healthcare professionals become more familiar with personalized medicine and targeted therapies, the demand for therapeutic vaccines is anticipated to grow.

Company Profiles

Key players in the therapeutic vaccines market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon. These companies are pursuing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative products.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America Therapeutics Vaccine Market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the South & Central America Therapeutics Vaccine Market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America Therapeutics vaccine Market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

Table of Contents

118 Pages
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. South & Central America Therapeutic Vaccines Market - Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic Conditions
4.1.2 Increasing Investments and Funding for Vaccine Development
4.2 Market Restraints
4.2.1 Regulatory Challenges
4.3 Market Opportunities
4.3.1 Extending Product Pipeline
4.4 Future Trends
4.4.1 Advancements in Vaccine Technology
4.5 Impact of Drivers and Restraints:
5. Therapeutic Vaccines Market - South & Central America Market Analysis
5.1 South & Central America Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
5.2 South & Central America Therapeutic Vaccines Market Forecast Analysis
6. South & Central America Therapeutic Vaccines Market Analysis - by Product
6.1 Cancer Vaccine
6.1.1 Overview
6.1.2 Cancer Vaccine: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.2 Infectious Disease Vaccine
6.2.1 Overview
6.2.2 infectious Disease Vaccine: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.3 Others
6.3.1 Overview
6.3.2 Others: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
7. South & Central America Therapeutic Vaccines Market Analysis - by Technology
7.1 Allogenic Vaccine
7.1.1 Overview
7.1.2 Allogenic Vaccine: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
7.2 Autologous Vaccine
7.2.1 Overview
7.2.2 Autologous Vaccine: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8. South & Central America Therapeutic Vaccines Market Analysis - by End User
8.1 Hospitals
8.1.1 Overview
8.1.2 Hospitals: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.2 Clinics
8.2.1 Overview
8.2.2 Clinics: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.3 Others
8.3.1 Overview
8.3.2 Others: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9. South & Central America Therapeutic Vaccines Market - Country Analysis
9.1 South & Central America
9.1.1 South & Central America Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
9.1.1.1 South & Central America Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
9.1.1.2 Brazil: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.2.1 Brazil: South & Central America Therapeutic Vaccines Market Share - by Product
9.1.1.2.2 Brazil: South & Central America Therapeutic Vaccines Market Share - by Technology
9.1.1.2.3 Brazil: South & Central America Therapeutic Vaccines Market Share - by End User
9.1.1.3 Argentina: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.3.1 Argentina: South & Central America Therapeutic Vaccines Market Share - by Product
9.1.1.3.2 Argentina: South & Central America Therapeutic Vaccines Market Share - by Technology
9.1.1.3.3 Argentina: South & Central America Therapeutic Vaccines Market Share - by End User
9.1.1.4 Rest of South & Central America: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.4.1 Rest of South & Central America: South & Central America Therapeutic Vaccines Market Share - by Product
9.1.1.4.2 Rest of South & Central America: South & Central America Therapeutic Vaccines Market Share - by Technology
9.1.1.4.3 Rest of South & Central America: South & Central America Therapeutic Vaccines Market Share - by End User
10. Therapeutic Vaccines Market - Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Therapeutic Vaccines Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Dendreon
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 BioNTech SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Serum Institute of India Pvt. Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Merck & Co Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Amgen Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 ISA Pharmaceuticals BV
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 INOVIO Pharmaceuticals Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Transgene SA
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 THERAVECTYS SA
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 CureVac SE
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
List of Tables
Table 1. South & Central America Therapeutic Vaccines Market Segmentation
Table 2. South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Table 3. South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Product
Table 4. South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Technology
Table 5. South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by End User
Table 6. South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Country
Table 7. Brazil: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 8. Brazil: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 9. Brazil: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 10. Argentina: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 11. Argentina: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 12. Argentina: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 13. Rest of South & Central America: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 14. Rest of South & Central America: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 15. Rest of South & Central America: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 16. Recent Organic Growth Strategies in the Therapeutic Vaccines Market
Table 17. Recent Inorganic Growth Strategies in the Therapeutic Vaccines Market
Table 18. Glossary of Terms, Therapeutic Vaccines Market
 
List of Figures
Figure 1. South & Central America Therapeutic Vaccines Market Segmentation - Country
Figure 2. South & Central America Therapeutic Vaccines Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. South & Central America Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
Figure 5. South & Central America Therapeutic Vaccines Market Share (%) - by Product (2024 and 2031)
Figure 6. Cancer Vaccine: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 7. infectious Disease Vaccine: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 8. Others: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 9. South & Central America Therapeutic Vaccines Market Share (%) - by Technology (2024 and 2031)
Figure 10. Allogenic Vaccine: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 11. Autologous Vaccine: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 12. South & Central America Therapeutic Vaccines Market Share (%) - by End User (2024 and 2031)
Figure 13. Hospitals: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 14. Clinics: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 15. Others: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 16. South & Central America Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 17. Brazil: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 18. Argentina: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 19. Rest of South & Central America: South & Central America Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 20. Growth Strategies in the Therapeutic Vaccines Market
 

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us